{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:23:59Z","timestamp":1789759439325,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regenerative Therapy"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.reth.2021.08.010","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T20:02:11Z","timestamp":1631217731000},"page":"339-346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Characterization of autologous platelet rich plasma (PRP) and its biological effects in patients with Beh\u00e7et's Disease"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3322-0598","authenticated-orcid":false,"given":"Stephany Cares","family":"Huber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silmara Aparecida","family":"de Lima Montalv\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoraida","family":"Sachetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Fabio","family":"Santos Duarte Lana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce Maria","family":"Annichino-Bizzacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.reth.2021.08.010_bib1","first-page":"107","volume":"vol. 14","author":"Yazici","year":"2018"},{"key":"10.1016\/j.reth.2021.08.010_bib2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/ar757","article-title":"Beh\u00e7et's disease","volume":"5","author":"Hirohata","year":"2003","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reth.2021.08.010_bib3","first-page":"215","article-title":"The evaluation of coagulation parameters and vessel involvement in Behcet's s disease. A clinical experience of Behcet's s disease: study of 152 cases","volume":"51","author":"Harman","year":"2013","journal-title":"Acta Med Iran"},{"key":"10.1016\/j.reth.2021.08.010_bib4","first-page":"S6","article-title":"Beh\u00e7et\u2019s disease: an update on the pathogenesis","volume":"19","author":"G\u00fcl","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reth.2021.08.010_bib5","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/1756-185X.12153","article-title":"The status of serum vitamin D in patients with active Behcet's disease compared with controls","volume":"17","author":"Alireza","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.reth.2021.08.010_bib6","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.4049\/jimmunol.1202677","article-title":"Role of IL-22- and TNF- -producing Th22 cells in uveitis patients with behcet's disease","volume":"190","author":"Sugita","year":"2013","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.reth.2021.08.010_bib7","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.intimp.2013.07.017","article-title":"Possible mechanisms of neutrophil activation in Beh\u00e7et\u2019s disease","volume":"17","author":"Neves","year":"2013","journal-title":"Int Immunopharmacol. Elsevier B.V"},{"key":"10.1016\/j.reth.2021.08.010_bib8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/ar3005","article-title":"Natural killer cells control a T-helper 1 response in patients with Beh\u00e7et\u2019s disease","volume":"12","author":"Yamaguchi","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reth.2021.08.010_bib9","first-page":"S71","article-title":"CD4\u00a0+ CD25\u00a0+ regulatory T cells in patients with Beh\u00e7et \u2019 s disease","volume":"5","author":"Hamzaoui","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reth.2021.08.010_bib10","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s10067-006-0484-y","article-title":"Cross-cultural adaptation of the Beh\u00e7et's disease current activity form (BDCAF) to the Brazilian Portuguese language","volume":"26","author":"Neves","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reth.2021.08.010_bib11","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/art.27581","article-title":"Long-term remission after cessation of interferon-\u03b1 treatment in patients with severe uveitis due to Beh\u00e7et\u2019s disease","volume":"62","author":"Deuter","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reth.2021.08.010_bib12","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/archophthalmol.2011.3","article-title":"Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behcet uveitis","volume":"129","author":"Samru","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.reth.2021.08.010_bib13","doi-asserted-by":"crossref","first-page":"147e","DOI":"10.1097\/01.prs.0000239606.92676.cf","article-title":"Platelet-rich plasma: a review of biology and application in plastic surgery","volume":"118","author":"Eppley","year":"2006","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.reth.2021.08.010_bib14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.joms.2003.12.003","article-title":"Platelet-rich plasma: evidence to support its use","volume":"62","author":"Marx","year":"2004","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.reth.2021.08.010_bib15","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1002\/art.30547","article-title":"Intraarticular injection of platelet-rich plasma reduces inflammation in a pig model of rheumatoid arthritis of the knee joint","volume":"63","author":"Lippross","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reth.2021.08.010_bib16","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2217\/rme.13.59","article-title":"Platelet-rich plasma: underlying biology and clinical correlates","volume":"8","author":"Andia","year":"2013","journal-title":"Regen Med"},{"key":"10.1016\/j.reth.2021.08.010_bib17","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/JSA.0b013e3182999712","article-title":"The basic science of platelet-rich plasma (PRP): what clinicians need to know","volume":"21","author":"Arnoczky","year":"2013","journal-title":"Sports Med Arthrosc"},{"key":"10.1016\/j.reth.2021.08.010_bib18","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/j.1537-2995.2006.00869.x","article-title":"Release of potential immunomodulatory factors during platelet storage","volume":"46","author":"Cognasse","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.reth.2021.08.010_bib19","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/nri2956","article-title":"Platelets and the immune continuum","volume":"11","author":"Semple Jon","year":"2011","journal-title":"Nat Rev Immunol"},{"issue":"67","key":"10.1016\/j.reth.2021.08.010_bib20","first-page":"1","article-title":"Platelet-rich paslam preparation for regnerative medicine: optimization and wuatification of cytokines and growth factors","volume":"4","author":"Amable","year":"2013","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.reth.2021.08.010_bib21","first-page":"2","article-title":"In\u00a0vitro study of the role of thrombin in platelet rich plasma (PRP) preparation: utility for gel formation and impact in growth factors release","volume":"12","author":"Huber","year":"2016","journal-title":"J\u00a0Stem Cells Regen Med"},{"key":"10.1016\/j.reth.2021.08.010_bib22","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s00296-011-1921-z","article-title":"Beh\u00e7et\u2019s disease in Brazilian patients: demographic and clinical features","volume":"32","author":"Sachetto","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.reth.2021.08.010_bib23","first-page":"152","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol Ver"},{"key":"10.1016\/j.reth.2021.08.010_bib24","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199802123380706","article-title":"Chemokines: chemotactic cytokines that mediate inflammation","volume":"338","author":"Luster","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.reth.2021.08.010_bib25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.chom.2008.07.003","article-title":"Platelet factor 4 mediates inflammation in experimental cerebral malaria","volume":"4","author":"Srivastava","year":"2008","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.reth.2021.08.010_bib26","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.4049\/jimmunol.174.5.2680","article-title":"Platelet factor 4 differentially modulates CD4+CD25+ (regulatory) versus CD4+CD25- (nonregulatory) T cells","volume":"174","author":"Liu","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.reth.2021.08.010_bib27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1172\/JCI71858","article-title":"Platelet factor 4 limits Th17 differentiation and cardiac allograft rejection","volume":"124","author":"Shi","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.reth.2021.08.010_bib28","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.4049\/jimmunol.167.3.1245","article-title":"CD4+CD25high regulatory cells in human peripheral blood","volume":"167","author":"Baecher-Allan","year":"2001","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.reth.2021.08.010_bib29","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1084\/jem.20040165","article-title":"Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-tnf\u03b1 therapy","volume":"200","author":"Ehrenstein","year":"2004","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.reth.2021.08.010_bib30","doi-asserted-by":"crossref","first-page":"14779","DOI":"10.1021\/bi0018180","article-title":"Crystal structure of human CD69: a C-type lectin-like activation marker of hematopoietic cells","volume":"39","author":"Natarajan","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.reth.2021.08.010_bib31","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.molmed.2013.07.006","article-title":"Is CD69 an effective brake to control inflammatory diseases?","volume":"19","author":"Gonz\u00e1lez-Amaro","year":"2013","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.reth.2021.08.010_bib32","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3109\/08923979909007126","article-title":"CD69 and regulation of the immune function","volume":"21","author":"Marzio","year":"1999","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.reth.2021.08.010_bib33","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1084\/jem.168.5.1621","article-title":"Triggering of T cell proliferation through AIM an activation inducer molecule expressed on activated human lymphocytes","volume":"168","author":"Cebrian","year":"1988","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.reth.2021.08.010_bib34","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.clim.2007.12.010","article-title":"CD4+CD25+ regulatory T cells (TREG) in systemic lupus erythematosus (SLE) patients: the possible influence of treatment with corticosteroids","volume":"127","author":"Azab","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.reth.2021.08.010_bib35","doi-asserted-by":"crossref","first-page":"134\u2014141","DOI":"10.1111\/j.1365-2567.2005.02220.x","article-title":"Circulating and thymic CD4+CD25+ T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment","volume":"116","author":"Fattorossi","year":"2005","journal-title":"Immunology"},{"key":"10.1016\/j.reth.2021.08.010_bib36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1600-0404.2008.01090.x","article-title":"Glucocorticoids increase CD4CD25 cell percentage and Foxp3 expression in patients with multiple sclerosis","volume":"119","author":"Braitch","year":"2009","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.reth.2021.08.010_bib37","doi-asserted-by":"crossref","first-page":"35237","DOI":"10.1074\/jbc.R114.619304","article-title":"Complexity of danger: the diverse nature of damage-associated molecular patterns","volume":"289","author":"Schaefer","year":"2014","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.reth.2021.08.010_bib38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1600-0714.2009.00774.x","article-title":"Treatment with levamisole and colchicine can result in a significant reduction of IL-6, IL-8 or TNF-\u03b1 level in patients with mucocutaneous type of Behcet's disease","volume":"38","author":"Sun","year":"2009","journal-title":"J\u00a0Oral Pathol Med"}],"container-title":["Regenerative Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352320421000699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352320421000699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:44:09Z","timestamp":1762451049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352320421000699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":38,"alternative-id":["S2352320421000699"],"URL":"https:\/\/doi.org\/10.1016\/j.reth.2021.08.010","relation":{},"ISSN":["2352-3204"],"issn-type":[{"value":"2352-3204","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of autologous platelet rich plasma (PRP) and its biological effects in patients with Beh\u00e7et's Disease","name":"articletitle","label":"Article Title"},{"value":"Regenerative Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reth.2021.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}